Allergan Plc (AGN)

200.15
NYSE : Health Technology
Prev Close 198.74
Day Low/High 198.00 / 200.40
52 Wk Low/High 114.27 / 202.22
Avg Volume 2.29M
Exchange NYSE
Shares Outstanding 328.28M
Market Cap 65.24B
EPS -16.00
P/E Ratio N/A
Div & Yield 2.96 (1.49%)

Latest News

Decisions, Decisions: AbbVie or Bristol-Myers Squibb?

Decisions, Decisions: AbbVie or Bristol-Myers Squibb?

AbbVie's weekly chart indicates its stock has room to run long term, but its daily chart suggests a rally in its shares is not imminent.

A Technical Strategy for AbbVie as the Broader Market Gets Rocked

A Technical Strategy for AbbVie as the Broader Market Gets Rocked

ABBV could bounce today but there remains the risk of a deeper correction.

Jim Cramer: 6 Stocks to Buy on Coronavirus Fears

Jim Cramer: 6 Stocks to Buy on Coronavirus Fears

These companies all could be strong -- even if the 2019 nCoV fear spreads.

Plenty of Reasons to Remain Bullish on Real Money Post Industrial Average

Plenty of Reasons to Remain Bullish on Real Money Post Industrial Average

Let's review 2019 performance of RMPIA in relation to stock indexes and see what's ahead.

This Dividend Aristocrat Is Our Top Pick for 2020

This Dividend Aristocrat Is Our Top Pick for 2020

As it smooths out the wrinkles from 2019, this pharmaceutical manufacturer should have a healthy year.

Individual Investors Are Back! Trading Cisco: Market Recon

Individual Investors Are Back! Trading Cisco: Market Recon

It seemed to happen overnight. People watched. People listened. People cared. About what? Individual stocks.

Allergan Cut to Neutral at UBS

Cash Stashes Dwindle as Markets Crest and Powell Speaks: Market Recon

Cash Stashes Dwindle as Markets Crest and Powell Speaks: Market Recon

Plus, we preview Wednesday's Trump-Erdogan meeting and check out AbbVie's huge debt offering as well as the new Abode-Microsoft connection.

The Price of Fair Trade, Defense Stocks Volatility, Eyes on InMode: Market Recon

The Price of Fair Trade, Defense Stocks Volatility, Eyes on InMode: Market Recon

Investors must understand that the narrative around trade with China has evolved as the two sides work on a 'Phase One' mini-trade deal, but this is about much more than that.

Jim Cramer: Drug Stocks Are Too Cheap

Jim Cramer: Drug Stocks Are Too Cheap

These stocks are priced for total imperfection. That's just what you want.

6 Top Biopharmaceutical Stock Picks You Should Know About

6 Top Biopharmaceutical Stock Picks You Should Know About

The aging population is creating a massive tailwind for companies that provide cutting-edge health care.

The Long Decline in AbbVie Is Over

The Long Decline in AbbVie Is Over

In addition to the yield let's check out the charts of ABBV.

Jim Cramer: Where Can You Still Get Some Growth and a Big Yield?

Jim Cramer: Where Can You Still Get Some Growth and a Big Yield?

Right now, AbbVie is the best way to capitalize on the moment and on the future.

My Outlook for the Market's Major Sectors

* Only three of eleven S&P sectors are viewed as attractive * I am in a risk off state of mind. Back in 2015 I instituted a new regular feature called "Sectors," in which I periodically offered my short-term (6-12 months) price outlook for each of t...

These Drug Cos. Could Soon Feel Big Side Effects of Opioid Crisis

These Drug Cos. Could Soon Feel Big Side Effects of Opioid Crisis

No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.

Evolus Could See Breakout Soon

Evolus Could See Breakout Soon

EOLS appears to have formed a small triangle pattern the past few weeks and a breakout is likely before reaching the apex.

AbbVie: The Right Mixture for the Perfect Stock

AbbVie: The Right Mixture for the Perfect Stock

ABBV has a positive earnings-per-share growth, an expanding price-to-earnings multiple and dividends that could result in annual shareholder returns well above 20%.

Real Money Post-Industrial Average Leads Major Indexes So Far for Year

Real Money Post-Industrial Average Leads Major Indexes So Far for Year

In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.

Big Pharma Sees Pockets of Recent Insider Buying

Big Pharma Sees Pockets of Recent Insider Buying

AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.

Powell's Verbal Fouls, an Equity Beatdown and Silence of the Lam: Market Recon

Powell's Verbal Fouls, an Equity Beatdown and Silence of the Lam: Market Recon

The Fed chairman's news conference threw markets for a loop with hawkish words that did not support the Fed's dovish actions.

Jim Cramer: Don't Play Earnings Season, Invest in It

Jim Cramer: Don't Play Earnings Season, Invest in It

Here are my five rules for handling earnings season.

Buyout Speculation Picks Up in Biotech

Buyout Speculation Picks Up in Biotech

Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.

Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019

Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019

There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.

AbbVie Insiders Buying Shares

Stocks see a nice surge on the open on optimism around trade talks resuming between the U.S. and China, although negotiations will be ongoing for many months and no permanent resolution seems on the horizon. The U.S. PMI Manufacturing Index also cam...

Now at the Plate, Your Pinch Hitter, Bret Jensen!

It is good to be sitting in for Doug Kass here on The Daily Diary as we open trading in the second half of 2019. June ended on an up note as all the major indices drifted up last week to close out the month and quarter. The market did an admirable j...

My 3 Predictions for the Second Half of 2019

My 3 Predictions for the Second Half of 2019

Watch the Russell 2000, housing activity, and mergers and acquisitions.

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.